Buy Waylivra (volanesorsen)

What is Waylivra (volanesorsen)?

Buy Waylivra (volanesorsen). Waylivra (volanesorsen) is a treatment for adults with a rare genetic condition called familial chylomicronemia syndrome (FCS). It helps those at high risk for pancreatitis. This is for people who haven’t seen enough improvement from diet and other treatments.

How does Waylivra (volanesorsen) work?

Waylivra contains volanesorsen, a short RNA piece. It’s designed to stop a protein that slows down fat breakdown. This protein is called apolipoprotein C-III.

By stopping this protein, Waylivra lowers blood triglycerides. This reduces fat in the body. It also lowers the risk of pancreatitis.

Where has Waylivra (volanesorsen) been approved?

Waylivra (volanesorsen) is approved for FCS by:

• European Medicines Agency (EMA) on May 3, 2019

This medicine might also be approved in other places. If you have questions about its approval in a specific country, contact our support team.

How is Waylivra (volanesorsen) taken?

Waylivra is given as 285 mg in 1.5 mL injected subcutaneously once weekly. It comes in a single-use prefilled syringe.

After 3 months, if triglycerides levels drop enough, the dose can be every 2 weeks. The dose is adjusted again after 6 and 9 months based on how well it works.

Remember, always talk to your doctor about the right dose for you.

Are there any known side effects or adverse reactions of Waylivra (volanesorsen)?

Common adverse reactions

The common side effects include:

• Asthenia
• Fatigue
• Nausea
• Headache
• Leukopenia
• Immunisation reaction
• Haematoma
• Epistaxis
• Erythema
• Myalgia

Serious adverse reactions

Waylivra can lower blood platelet levels. This is the main risk, as it can cause severe bleeding.

So, patients need close monitoring. The dose might need to be adjusted if needed.

Contraindications

• Hypersensitivity to the active substance (volanesorsen) or to any of the following ingredients: sodium hydroxide (for pH adjustment), hydrochloric acid (for pH adjustment), water for injections.
• Chronic or unexplained thrombocytopenia. Treatment should not be initiated in patients with thrombocytopenia (platelet count <140 x 109/L).

For a full list of side effects and adverse reactions, see the official prescribing information.

 

Use in specific populations

Elderly population

No dose adjustment is needed for elderly patients. There’s limited data for those 65 and older.

Patients with renal impairment

No dose adjustment is needed for mild to moderate renal impairment. But, safety and efficacy in severe impairment are not established. These patients should be closely watched.

Patients with hepatic impairment

This medicinal product has not been studied in patients with liver problems. It is not broken down by the liver’s cytochrome P450 system. So, changing the dose for liver issues is unlikely.

Paediatric population

The safety and effectiveness of this product in kids and teens under 18 have not been proven. There is no data available.

Buy Vascepa (icosapent ethyl)